Anupam Rasayan India has entered into a definitive agreement to acquire 43.3-48.2% equity stake + Open Offer to the public shareholders of Bliss GVS Pharma, an India-based pharmaceutical formulations company. The total purchase consideration has been financed via term loan Rs 300 crore and non-controlling non-voting equity instrument for the balance amount.
This will strategically strengthen the company’s presence across the pharmaceutical value chain, spanning KSMs to finished dosage formulations. Bliss GVS Pharma brings well-established capabilities in niche dosage forms, a strong international footprint, differentiated brands, and expertise across multiple therapeutic segments.
Together with the company's advanced chemistry capabilities, the combined platform would create a broader integrated and diversified pharmaceutical manufacturing ecosystem with deeper backward integration, enhanced global reach especially in the Europe and America market, further strengthen by Jayhawk acquisition.
Anupam Rasayan India is one of the leading companies engaged in the custom synthesis (CSM) and manufacturing of specialty chemicals in India.
